Benzinga | Jan 25, 2021 08:05AM EST

aTyr Pharma To Present A Poster On NRP2 And Participate In Q&A Session At Virtual Keystone Symposia: Tumor Metabolism and the Microenvironment Jan. 27

Poster highlights NRP2 expression on immune cells in the tumor microenvironment.



Company's lead NRP2 antibody, ATYR2810, is in development for oncology.

SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and participate in a live Q&A session at the Virtual Keystone Symposia: Tumor Metabolism and the Microenvironment, which is being held January 25 -- 28, 2021. The abstract and poster are available on the Keystone Symposia website.

The poster presents preclinical findings demonstrating that Neuropilin-2 (NRP2) was highly expressed on key immune cells implicated in regulating cancer progression, including myeloid derived suppressor cells (MDSCs), tumor associated macrophages (TAMs) generated from triple negative breast cancer cell lines, mature dendritic cells (DCs), and inducible T regulatory cells (Tregs). Further research showed that MDSCs and TAMs suppressed T cell proliferation and activation.

Details of the abstract and poster presentation are as follows:

Title: Neuropilin-2 is Expressed on Immune Cells Present in the Tumor Microenvironment, and May Contribute to the Suppression of Immune Regulation Leading to Progression and Metastasis of Cancer

Authors: Samantha Tyler, Michaela Ferrer, Clara Polizzi, Rodrigo Da Silva, Lisa Eide, Kendall Walwick, Matt Seikkula, Christoph Burkart, Suzanne Paz, Leslie Nangle. aTyr Pharma, San Diego, CA.

Session: Poster Session 2

Live Q&A Date and Time: January 27, 2021, 4:00 -- 5:00PM EST